World’s Premiere Science Journal Touts Revolutionary Innovations by RBCC Partner Nano3D
May 06 2013 - 5:00AM
Business Wire
Nature, the world’s premiere science journal, has finally caught
on to what Rainbow Coral Corp. (OTCBB: RBCC) has known for some
time: The cell-growth technology pioneered by RBCC partner n3D
Biosciences has the potential to completely revolutionize cellular
research.
n3D’s magnetic levitation technology was the subject of a
feature article in the journal’s April issue titled “A Better
Brew.” The system allows researchers at university laboratories and
pharmaceutical companies to grow three-dimensional, lifelike
microtissues similar enough to those found within the body to be
used in in vivo drug-testing models. RBCC signed a joint venture
agreement to help market and develop the technology last year.
The abstract of the article is available now at n3D’s website
http://www.n3dbio.com/a-better-brew-nature-technology-review-on-cell-culture/.
The high-profile feature is certain to spread the word on n3D’s
groundbreaking magnetic levitation system to labs across the globe
at a time when researchers are eagerly adopting and evaluating 3-D
cell-growth formats, says RBCC CEO Patrick Brown.
“We strongly believe that n3D’s levitation technology is the
future of cellular research,” Brown said. “We anticipate an
explosion of interest in the company and its products as a result
of this terrific Nature article.”
Rainbow BioSciences, RBCC’s biotech division, signed a joint
venture agreement with n3D last year to help develop and market the
Bio-Assembler. For more information on this and other biotech
initiatives, please visit
www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research
technology innovations to compete alongside companies such as
Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc.
(NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen
Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of
Rainbow Coral Corp. (OTCBB: RBCC). The Company continually
seeks out new partnerships with biotechnology developers to deliver
profitable new medical technologies and innovations. For more
information on our growth-oriented business initiatives, please
visit www.RainbowBioSciences.com. For investment information
and performance data on the Company, please
visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995: This news release contains forward-looking
information within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including statements that include the words
"believes," "expects," "anticipate" or similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the Company to differ materially
from those expressed or implied by such forward-looking statements.
In addition, description of anyone's past success, either financial
or strategic, is no guarantee of future success. This news release
speaks as of the date first set forth above and the Company assumes
no responsibility to update the information included herein for
events occurring after the date hereof.